Kiva Genetics: Clinical grade genetic analysis

If pharmacogenomics is truly to affect the future of drug development, patients with a wide variety of diseases will have to be screened for particular genetic markers prior to enrollment in clinical trials, and those markers will have to be identified and validated in the first place. Kiva Genetics Inc. proposes to be the company to do that screening through its high-throughput genotyping technology and genetic services business model.

Kiva's genotyping technology relies on microchannel electrophoretic DNA

Read the full 760 word article

How to gain access

Continue reading with a
two-week free trial.